Doordash Takes Huge Bite Out of Competition with Nearly 300% Increase in Purchases, Say Emburse Expense Data
‘Most Expensed Meals’ data reveals which food brands American workers favor; Starbucks, McDonald’s top the…
‘Most Expensed Meals’ data reveals which food brands American workers favor; Starbucks, McDonald’s top the…
SAN DIEGO–(BUSINESS WIRE)–Please replace the release with the following corrected version due to multiple revisions….
SAN FRANCISCO–(BUSINESS WIRE)–Lang.ai has announced its completion of a $10.5M Series A led by Nava…
NEW YORK–(BUSINESS WIRE)–#KBRA–KBRA assigns preliminary ratings to five classes of notes issued by Carvana Auto…
RESTON, Va.–(BUSINESS WIRE)–$IWLLC #CEOs—Intelligent Waves (IW), a leading IT integrator that provides mission-focused, multi-domain operational…
Within two months the beauty brand saw a 60% increase in conversion rate and doubled…
Smartest, most-awarded panel on the market now available for order from electrical distribution centers Innovative…
Accepted abstracts include an oral presentation highlighting quality of life improvements with EMPAVELI® (pegcetacoplan) WALTHAM, Mass.,…
– AUTO4: oral presentation on initial clinical experience in peripheral T cell lymphoma– AUTO1/22: oral…
CAMBRIDGE, Mass., May 12, 2022 (GLOBE NEWSWIRE) — In a release issued under the same…
Favorable safety profile, high overall response and complete response rates, and CAR T persistence observed…
ZUG, Switzerland and CAMBRIDGE, Mass., May 12, 2022 (GLOBE NEWSWIRE) — CRISPR Therapeutics (Nasdaq: CRSP),…
The novel bispecific innate cell engager AFM28 stimulates NK cells to destroy CD123-positive tumor cells…
Latest in HR+/HER2- metastatic breast cancer, including data on CDK recycling with Kisqali® plus endocrine…
Posters include preclinical data on SYK inhibition in combination with targeted agents and demonstrate preclinical…
Media Release Copenhagen, Denmark, May 12, 2022 Multiple epcoritamab (DuoBody®-CD3xCD20) studies will be presented showcasing…
Clinical Updates for HM43239 and Luxeptinib Poster Presentation for HM43239 is Scheduled for June 10th…
– Agios to Present New Patient-Reported Outcomes (PRO) Data from ACTIVATE Phase 3 Study of…
Poster to highlight initial data from on-going Phase 2 APEX trial evaluating bezuclastinib in patients…
New real-world evidence data on Oxbryta® (voxelotor) from multicenter RETRO Study and new Phase 1…